Organization
Mount Sinai Beth Israel
9 abstracts
Abstract
Association between somatic mutation pathways and treatment response in patients with biliary tract cancers (BTCs).Org: Beth Israel Deaconess Medical Center, Mount Sinai Beth Israel, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Arthralgia in patients with cancer receiving immune checkpoint inhibitor: A systematic review and meta-analysis.Org: University of Hawaii Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, John A. Burns School of Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel,
Abstract
Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 randomized controlled trials.Org: Mount Sinai Beth Israel, Mount Sinai Hospital-Breast Medical Oncology, Kyoto University Hospital, Center for Thoracic Oncology, Tisch Cancer Institute,
Abstract
C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Hospital, Mount Sinai Beth Israel, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
The incidence of thyroid-related adverse events in solid tumors receiving immune checkpoint blockade with curative intent: A meta-analysis.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel, Yokohama City University Hospital, The Tisch Cancer Institute,
Abstract
Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategies.Org: Mount Sinai Beth Israel, Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
C-reactive protein (CRP) as a prognostic biomarker in patients with bladder cancer: A meta-analysis.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel, Mount Sinai Hospital, The Tisch Cancer Institute,
Abstract
ASSOCIATION BETWEEN USE OF TRADITIONAL CHINESE MEDICINE AND MEDICATION ADHERENCE AMONG CHINESE-AMERICAN RHEUMATOLOGY PATIENTS Org: Hospital for Special Surgery, New York University School of Medicine, Mount Sinai Beth Israel, Memorial Sloan Kettering Cancer Center, New York, United States,